Comparison between l-CHOP and an l-CHOP protocol with interposed treatments of CCNU and MOPP (l-CHOP-CCNU-MOPP) for lymphoma in dogs

• Published in: Veterinary & comparative oncology Vol. 8; no. 4; pp. 243 - 253
• Main Authors: Rassnick, K. M., Bailey, D. B., Malone, E. K., Intile, J. L., Kiselow, M. A., Flory, A. B., Barlow, L. L., Balkman, C. E., Barnard, S. M., Waite, A. H.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.12.2010
• Subjects: Animals; anticarcinogenic activity; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; asparaginase; Asparagine - administration & dosage; Asparagine - therapeutic use; chemotherapy; combination drug therapy; cyclophosphamide; Cyclophosphamide - administration & dosage; Cyclophosphamide - therapeutic use; disease course; disease severity; dog diseases; Dog Diseases - drug therapy; Dogs; doxorubicin; Doxorubicin - administration & dosage; Doxorubicin - therapeutic use; drug synergism; Female; Lomustine - administration & dosage; Lomustine - therapeutic use; lymphoma; Lymphoma - drug therapy; Lymphoma - veterinary; Male; Mechlorethamine - administration & dosage; Mechlorethamine - therapeutic use; methodology; neutropenia; oncology; prednisone; Prednisone - administration & dosage; Prednisone - therapeutic use; Procarbazine - administration & dosage; Procarbazine - therapeutic use; Retrospective Studies; Risk Factors; small animal; vincristine; Vincristine - administration & dosage; Vincristine - therapeutic use
• ISSN: 1476-5810; 1476-5829; 1476-5829
• DOI: 10.1111/j.1476-5829.2010.00224.x

An l‐CHOP protocol with interposed treatments of CCNU and MOPP (l‐CHOP‐CCNU‐MOPP) was evaluated in 66 dogs with stages III–V lymphoma. Results were compared with a historical group of 71 dogs treated with an l‐CHOP protocol. Complete remission (CR) rates (85 and 80%, respectively) did not differ significantly between protocols (P = 0.48). First CR duration for dogs treated with l‐CHOP‐CCNU‐MOPP was significantly longer: median, 317 days; 2‐year CR rate, 35% versus median, 298 days; 2‐year CR rate, 13%, P = 0.05). For the l‐CHOP‐CCNU‐MOPP protocol, dogs in substage‐b had a 4.3 times greater hazard of having a relapse than dogs in substage‐a (P = 0.002). Frequency of adverse chemotherapy‐associated gastrointestinal effects did not differ between protocols (P = 0.77). Neutropenia (primarily after CCNU) occurred more frequently in dogs treated with l‐CHOP‐CCNU‐MOPP (P < 0.001). In summary, the l‐CHOP‐CCNU‐MOPP protocol showed an improved duration of first CR as compared with an l‐CHOP protocol, but the relevance of this finding might be subject to clinical judgement.